Specific inhibition of caspase-2 activation for the treatment of neurodegenerative diseases
- Summary
- This technology is a membrane-permeable hexapeptide that specifically inhibits caspase-2 signaling in the central nervous system to treat neurodegenerative diseases.
- Technology Benefits
- Specifically inhibits caspase-2 signalingDoes not interfere with other cellular pathways in the brainPenetrates cell membranes for enhanced drug delivery
- Technology Application
- Treatment of neurodegenerative diseases, including Alzheimer’s disease, mild cognitive impairment Parkinson’s disease, Huntington’s chorea, amyotrophic lateral sclerosis, and Creutzfeld-Jacob diseaseResearch tool for understanding the role of caspase-2 and RAIDD in cellular signaling
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU12019
- *Principal Investigator
-
- *Publications
- Jean YY, Ribe EM, Pero ME, Moskalenko M, Iqbal Z, Marks LJ, Greene LA, Troy CM. “Caspase-2 is essential for c-Jun transcriptional activation and Bim induction in neuron death” Biochem J. 2013 Oct 1; 455(1): 15-25. Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, Shelanski M. “Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice” Nat Commun. 2013 Jun 10; 4: 1939.Ribe EM, Jean YY, Goldstein RL, Manzl C, Stefanis L, Villunger A, Troy CM. “Neuronal caspase 2 activity and function requires RAIDD, but not PIDD” Biochem J. 2012 Jun 15; 444(3): 591-599.Tech Ventures Reference:IR CU12019Licensing Contact: Jerry Kokoshka
- Country/Region
- USA
For more information, please click Here
